When moving from the general population to patients with MASLD an Italian single centre study also reported that in 471 MASLD patients followed for a median of 64.6 months, PNPLA3 rs738409 C > G variant other than to increase the risk of liver decompensation and HCC, also exposed to a 3.5 times higher risk of liver‐related death, while no association was found with overall mortality [73]. The gene discussed is PNPLA3; the disease is hepatocellular carcinoma.